Loading...
XSHG
603229
Market cap968mUSD
Jul 09, Last price  
7.91CNY
1D
-0.50%
1Q
-21.84%
IPO
110.37%
Name

Zhejiang Ausun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603229 chart
P/E
50.30
P/S
8.35
EPS
0.16
Div Yield, %
1.26%
Shrs. gr., 5y
9.59%
Rev. gr., 5y
13.97%
Revenues
787m
-1.07%
58,930,964120,948,643201,417,277262,666,049198,841,957240,188,298243,885,062307,914,614409,249,349569,698,343764,547,388816,765,082795,288,308786,769,229
Net income
131m
-36.86%
2,293,87715,552,70221,501,01760,865,09157,328,09553,011,52243,864,09256,386,59586,836,033145,930,190235,375,830253,901,971206,791,018130,570,123
CFO
157m
-12.04%
-1,138,30015,729,90021,450,35653,626,06993,207,58846,784,77711,503,53687,729,755138,470,268173,900,860120,567,033221,847,783177,925,777156,508,914
Dividend
Jul 17, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2010 and headquartered in Linhai, China, Zhejiang Ausun Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of unique active pharmaceutical ingredients (APIs) and various intermediate compounds for drug synthesis. Its comprehensive portfolio includes fluorine-based compounds, prostaglandins, and anti-infectives, in addition to critical oncology therapeutics. The company also provides medications targeting liver, respiratory, cardiovascular, and cerebrovascular conditions, as well as central nervous system (CNS) disorders. Furthermore, Zhejiang Ausun Pharmaceutical is involved in contract processing services and continuous scientific research and development initiatives.
IPO date
May 09, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT